Ra Pharmaceuticals, Inc.
Q4 2019 13F Holders
Symbol
RARX
CUSIP
74933V108
Type
Equity
Class
COM
Num filings
171
Total reported value, excl. options
$2.37 B
Compare 2019 Q4 to
2020 Q2
2020 Q1
2019 Q3
2019 Q2
2019 Q1
2018 Q4
2018 Q3
2018 Q2
2018 Q1
2017 Q4
2017 Q3
2017 Q2
2017 Q1
2016 Q4
Manager
Report Date
Value ($000)
Shares
Option Type